Randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in Patients Wild-Type KRAS Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy.

Trial Profile

Randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in Patients Wild-Type KRAS Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Cetuximab (Primary) ; Panitumumab (Primary) ; Irinotecan
  • Indications Coecal cancer; Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Sep 2017 Results of a subgroup analyses evaluating homogeneity of treatment effects for PFS and OS presented at the 42nd European Society for Medical Oncology Congress
    • 21 Jan 2017 Status changed from active, no longer recruiting to completed according to results presented at the 2017 Gastrointestinal Cancers Symposium..
    • 21 Jan 2017 Primary endpoint of progression-free survival has been met, according to results presented at the 2017 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top